Matternet (OTCQB: MTTN) has found a sales channel for a drone it cannot yet fly commercially. On Oct. 29, the Mountain View company and Swisslog Healthcare's TransLogic announced a partnership that makes TransLogic's sales team a distribution channel for Matternet's M3 delivery drone and its dock. The target market is hospitals that already run TransLogic pneumatic tube systems.
On paper, that is a large market. According to the companies' press release, Swisslog Healthcare's automated transport systems operate in more than 2,300 North American hospitals, including 18 of the top 20 US hospitals. The release puts TransLogic's customer base at more than 3,000 hospitals worldwide, and DroneXL repeats that figure. The partners say their first US deployments will target California, Florida and Arizona during the first year of the partnership.
The aircraft is the problem. DroneXL reports that the M3 has no FAA type certificate. Matternet unveiled it on Sept. 28 and is targeting commercial service for the second half of 2027. The release names no hospital, and neither it nor DroneXL reports a price or an order count.
What the Deal Actually Is
This is a distribution deal, not a purchase contract. TransLogic's sales team will sell M3 systems into hospitals that already buy its pneumatic tube, pharmacy automation and specimen tracking products. Those are the facilities and logistics departments that already run the tube networks moving specimens, medications and documents between floors and buildings. The two companies also plan to explore having Swisslog Healthcare's field service organization install, support and maintain Matternet's docks at hospital sites, which would matter for rooftop hardware that has to be mounted, powered and serviced. That part is still something to be explored, not a settled term.
Swisslog Healthcare is the hospital arm of the German robot maker KUKA and has more than 1,000 employees, according to DroneXL. Swisslog Healthcare CEO Cory Kwarta and Matternet CEO Andreas Raptopoulos are both quoted in the release. Neither the release nor the coverage gives a revenue split, exclusivity terms or a minimum commitment.
The fit is easy to see. A pneumatic tube system moves small payloads quickly inside a campus. A drone can do a similar job between buildings and facilities that tubes cannot reach. Selling the drone as an extension of the tube network, through the vendor that already serves those hospitals, looks like a sensible way for a small company to reach procurement offices it would otherwise have to approach one hospital at a time.
The Aircraft
The companies describe the M3 as operating fully autonomously. It carries up to 11 lb within a 10-mile service radius and sits between flights in the M3 Dock, which Matternet says can be installed on a hospital rooftop or other underutilized space. The release lists medications, laboratory specimens and urgent supplies as the intended loads.
Matternet's previous aircraft, the M2, is the company's regulatory asset. The release says it is the only drone delivery system to achieve standard Type Certification and Production Certification from the FAA. The M3 is a new design and, as far as the sources show, does not inherit that approval. DroneXL notes that the release does not say which aircraft would fly the first-year deployments. Until the M3 completes its own certification, or flies under some other authorization the companies have not described, TransLogic's sales team will be offering hospitals a 2027 service rather than something they can install next quarter.
The Financial Picture
Matternet's most recent Form 10-Q, for the quarter ended June 30, 2026, shows how small the business still is:
- Quarterly revenue: $121,439, down from $130,321 a year earlier.
- Nine-month revenue: $255,564, down from $261,946.
- Cost of revenues: $340,882 for the quarter, for a gross loss of $219,443.
- Research and development: $964,846 for the quarter.
The M3 was not unveiled until September and has no commercial service date before 2027, so none of that revenue came from the new aircraft. DroneXL reports that all of it came from M2 operations. Matternet spent nearly three dollars in cost of revenues for each dollar of revenue in the quarter, before counting R&D, and its quarterly R&D spending was about eight times its quarterly sales. That fits a company still developing its product, and it helps explain why a partner with an existing hospital sales force is worth a press release before any orders exist. DroneXL also reports, citing the same filing, that the company expects its cash to run out within a year under its current plan and that management concluded substantial doubt exists about its ability to continue as a going concern.
Why It Matters
Hospital logistics is one of the more natural uses for drone delivery. Routes between facilities are fixed, payloads are small and urgent, and the customer is an institution rather than a consumer. DroneXL's editor argues that a tube-system representative who already works with 2,300 hospitals is worth more than any previous Matternet launch partner, because hospital logistics directors tend to buy from vendors they already have a service contract with. If TransLogic's field service organization ends up installing and maintaining docks, it would also address a gap in Matternet's US model, where other operators have flown its commercial routes.
But a distribution channel does not certify an aircraft. The headline figure of 2,300 hospitals measures TransLogic's installed base, not demand for drones, and the announcement has no named customer to test it against. The milestones that will show whether this partnership becomes a business are straightforward: an FAA type certificate for the M3, a first signed hospital in California, Florida or Arizona, and revenue lines in future filings that move well beyond the low six figures. Until then, it is a credible go-to-market plan for an aircraft that is still waiting on its paperwork.
